Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from MorningStar referenced a study published online ahead of print in the November 2024 issue of The American Journal of Managed Care®. The study, “Prescription Rebate Guarantees: Employer Insights,” focused on the role of employer benefits consultants and brokers in the selection of pharmacy benefit managers, as they may help in continuing the reliance on drug rebates, which are linked to higher list prices and higher out-of-pocket costs. Mark Cuban, owner of the Mark Cuban Cost Plus Drug Company, which buys and sells drugs at affordable prices, also shared the article on X.
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More